Lilly’s Latest Leadership Shuffle Gives CSO Skovronsky Immunology Oversight
Moves Follow Recent Anti-Inflammatory Program Setbacks
Executive Summary
Lilly Diabetes president Mike Mason is retiring, prompting a shifting of responsibilities among the executive team as the company gears up for key product approvals.